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For patients with a craniopharyngioma (CP), treatment of hypothalamic obesity (HO) and
hyperphagia following resection and/or radiotherapy is extremely difﬁcult and few reports
have been published on potential drug therapies. Psychomotor stimulant methylphenidate
(MPH) has been reported to inhibit food intake (FI). In this paper, we report reduction
of body mass index (BMI) and appetite in an adolescent CP patient suffering from HO.
We then tested the ability of MPH to attenuate the FI and body weight (BW) gain in a
rat model consistent with the neuroanatomical and metabolic disturbances commonly
observed in obese CP patients. Speciﬁcally, we used a novel electrolytically generated
combined medial hypothalamic lesion (CMHL) affecting the arcuate nucleus, ventrome-
dial hypothalamic nucleus, and dorsomedial hypothalamic nucleus to induce hyperphagia,
rapid weight gain, and adiposity. Both CMHL and control animals (n = 7 per group) were
administered either methylphenidate HCl (MPH; 20mgkg−1 day−1) or saline for 4 days in
a crossover design experiment 28weeks post-surgery. A signiﬁcant decrease in percent
baseline FI (CMHL −23%, p = 0.008; control −20%, p = 0.002) and percent change in BW
(CMHL −1.97%/4 days, p = 0.011; control −1.75%/4 days, p = 0.003) was observed during
MPH treatment as compared to saline. Conclusion:This study shows MPH treatment of
severely obese CMHL rats resulted in signiﬁcantly reduced FI and BW loss.
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INTRODUCTION
Severe hypothalamic obesity (HO) and hyperphagia are common
sequelae following tumor resection in child and adolescent cran-
iopharyngioma (CP) patients, ranging in rate from 22 to 62%
(Brauner et al., 1987; Sorva, 1988; Muller, 2008). Radical tumor
resection and subtotal tumor resection with or without radiother-
apy are the current therapeutic standard. Post-resection and/or
treatment, a distinct trend in weight gain has been observed in
childrenwhodevelopedHO. Speciﬁcally, a rapid gain in bodymass
index (BMI) SDS for the ﬁrst 6months followed by long-term sta-
bilization with little appreciable decline (Ahmet et al., 2006). Even
more distressing, attempts at weight loss through caloric restric-
tion and exercise are largely unsuccessful (Lustig et al., 2003; Eyal
et al., 2006). Pharmacological treatment of HO and hyperphagia
has shown success in a few clinical studies and case reports (Mason
et al., 2002; Lustig et al., 2003; Danielsson et al., 2007; Hamilton
et al., 2011) though weaker weight reductions were observed com-
pared to uncomplicated obesity (Danielsson et al., 2007). A recent
study of both normal weight and obese CP patients showed that
insulin resistance and altered gut hormone secretion are not exclu-
sively a result of obesity but hypothalamic disruption caused by
the tumor and/or its treatment (Roth et al., 2011b).
Animal models utilizing electrolytically and chemically gener-
ated lesions produce similar effects to those observed clinically
and are thereby an excellent model in which to study therapeu-
tic interventions for HO (Dawson et al., 1989; Tokunaga et al.,
1991, 1993; Schoelch et al., 2002; Leitner and Bartness, 2008).
Recently we developed a novel combined medial hypothalamic
lesion (CMHL) model that utilizes electrolytic lesions in the arcu-
ate nucleus (ARC), ventromedial hypothalamic nucleus (VMN),
and dorsomedial hypothalamic nucleus (DMN) to model the
sequelae commonly observed in HO resulting from resection
and/or treatment of CP (Roth et al., 2011a). Similar effects were
observed when combining chemically induced ARC lesion with
electrolytically induced VMN lesions (Elfers et al., 2011). Specif-
ically, the CMHL model exhibits rapid weight gain, hyperphagia,
hyperinsulinemia, and hyperleptinemia.
One potential therapeutic target for the treatment of hyper-
phagia in HO is the dopaminergic system. Methylphenidate HCl
(MPH), a psychomotor stimulant used in the treatment of atten-
tiondeﬁcit hyperactivity disorder in children,produces an increase
in brain synaptic dopamine (DA) signaling with the side effect of
anorexia (Leddy et al., 2009). However, there is variance in the
reported long-term ability of MPH to sustain weight loss ranging
from 3months to the duration of administration of a clinically
effective dose (Leddy et al., 2009).
The aim of our study was to test the inhibitory effect of MPH
treatment on food intake (FI) inournovelCMHLratmodel of HO.
We hypothesized that administration of MPH to severely obese
CMHL rats will result in reduction of FI and body weight (BW)
gain.
CASE REPORT
A 5.9-year-old male presented with short stature, headaches, nau-
sea, and vomiting. Neuroimaging (CT, MRI) indicated a large
sellar and suprasellar mass causing obstructive hydrocephalus.
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Following gross total resection of a large CP, the patient was
diagnosed with panhypopituitarism. Two years later the patient
underwent cranial radiation therapy due to tumor relapse. At the
time of tumor diagnosis, height was 110 cm (25th percentile),
weight 23.4 kg (75th percentile), and BMI 19.3 kg/m2 (+1.9 z-
score). Following resection, the patient noted a very low level of
energy, increased hunger, and difﬁculty becoming satiated. One
year post-tumor resection, height was 117 cm (25th percentile),
weight 34.1 kg (3 kg>97th percentile), and BMI 24.5 kg/m2 (+2.5
z-score).Despite optimal endocrinemanagement, the patient con-
tinued to experience signiﬁcant weight gain that was unable to be
mediated by lifestyle changes. As part of hormone replacement
therapy desmopressin acetate (DDAPV), hydrocortisone, growth
hormone, and levothyroxine were prescribed. At age 15 years,
height was 184 cm (>90th percentile), weight 154 kg (70 kg>97th
percentile), and BMI 45.5 kg/m2 (+2.9 z-score).
MPH was identiﬁed as a potential therapeutic to attenuate
hunger due to its frequently observed anorexic side effect. MPH
treatment began at age 15 years with a 20mg day−1 dose (morn-
ing: 10mg; evening: 10mg; 30–45min prior to meals) and was
gradually increased to 50mg day−1 dose (morning: 30mg; noon:
10mg; evening: 10mg; 30–45min prior to meals) over the course
of 10weeks. Following start of MPH treatment, overall weight gain
ceased (Figure 1) and patient noted a dose dependent decrease in
hunger. After 31weeks treatment, the MPH dose was adjusted to
60mg day−1 dose (morning: 30mg; noon: 10mg; evening: 20mg;
30–45min prior to meals) due to a slight increase in BMI. After
this last dose adjustment, the patient has had continued decrease
in BMI for over 56weeks.After 87weeks ofMPH treatment,height
was 186 cm (>90th percentile), weight 142 kg (47 kg >97th per-
centile), and BMI 41.4 kgm−2 (+2.8 z-score). It is important to
note that this patient was not under any exercise regimen during
FIGURE 1 | Changes of BMI in the patient course of methylphenidate
treatment. At the start of the methylphenidate treatment the patient was
76 kg over ideal weight given height and age. After 87weeks of treatment
the patient lost 12 kg of excess weight. ∗Start of methylphenidate treatment
(20mgday−1 dose; morning: 10mg; evening: 10mg). ∗∗Start of ﬁnal dose
(60mgday−1 dose; morning: 30mg; noon: 10mg; evening: 20mg).
this time and therefore any change in BMI is independent of
exercise.
MATERIALS AND METHODS FOR RAT STUDY
ANIMALS
Young adult male Sprague Dawley rats, weighing 250–260 g, were
purchased from Charles River Laboratory (Wilmington, MA,
USA). Animals were individually housed on a 12/12-h light/dark
cycle (lights on at 07:00 h) in a temperature (23˚C) and humid-
ity (50± 10%) controlled room.Ad libitum access to regular chow
(5053Pico LabRodentDiet,Purina LabDiet,Richmond,CA,USA)
and water was provided. Following surgery, the animals’ BW and
FI were recorded. All procedures performed were approved by the
Institutional Animal Care and Use Committee at the Seattle Chil-
dren’s Research Institute and were in accordance with the NIH
Guide for the Care and Use of Laboratory Animals.
ELECTROLYTIC LESION
To electrolytically induce the CMHL, animals were placed under
a surgical-plane of anesthesia (isoﬂurane/oxygen mix, 5% induc-
tion, 2–4% throughout the procedure) and were mounted in a
Kopf stereotaxic frame (Tujunga, CA, USA). The upper incisor
bar was 3.5mm above the interaural line. Lesions were targeted to
the ARC,VMN, and DMN through the placement of an insulated
stainless steel electrode at stereotaxic coordinates based on our
previous study (Roth et al., 2011a). Speciﬁcally, an anodal electric
current (110V, 1.7mA for 15 s) was passed through the tip of the
electrode while placed 2.6mm posterior to the bregma, 0.5mm
lateral to the midsagittal line, and both 10mm (ARC) and 8.6mm
(VMN/DMN) ventral from the skull according to the method
described in our recent paper (Roth et al., 2011a).
INJECTION OF METHYLPHENIDATE AND DATA COLLECTION
A crossover experimental design was utilized to determine the
effects of daily MPH injections (20mg kg−1 BW) on FI and BW.
For 6 days prior to the start of the injections, FI was recorded
and averaged to determine baseline values (n = 7 per group).
Four animals from each group received daily i.p. injections of
20mg kg−1 MPH (Letco Medical, Decatur, AL, USA) while three
animals from each group received i.p. saline injections (0.9%
sodium chloride inj., USP, Hospira) for a period of 4 days, after
which, the treatments were switched for an additional 4 days of
testing. Administration of all injections as well as measurement
of FI and BW occurred in the evening (18:30 h, 30min prior to
lights out). MPH has been show to have a half-life of approxi-
mately 1 h in rats (Kuczenski and Segal, 2002), therefore we did
not provide a washout period between treatments. Lee index [LI;
BW−1/3/snout to anus length (mm)]measures were taken pre- and
post-treatment as a indicator of total adiposity.
STATISTICAL ANALYSIS
Statistical analyses were performed using GraphPad Prism Soft-
ware (La Jolla,CA,USA).Outcome variables between study groups
were compared using Student’s t -tests for continuous variables.
Two-way ANOVA modeling with a Bonferroni post hoc was used
for contrasts of two factors between study groups. In all instances,
a two-sided p< 0.05 was considered signiﬁcant unless otherwise
stated.
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RESULTS FOR RAT STUDY
GENERAL RESULTS
Pre-surgery BW, body length (BL), and LI were comparable in
lesion and control groups (p = 0.539, p = 0.533, p = 0.122, respec-
tively). An immediate increase in FI and BW (1 day post-surgery)
was observed in the lesion group and signiﬁcant changes in BW
were observed 3weeks post-surgery (p = 0.034). At the time of
MPH treatment (28weeks post-surgery), there was a signiﬁcant
difference in pre-treatment LI (p = 0.025) indicating a greater
degree of obesity in the lesion group (Table 1).
BODY WEIGHT
Both control and lesion groups exhibited a slight trend of weight
gain during the 4 days of saline injection (control: 0.155± 0.213%
BW, lesion: 0.340± 0.388%BW). Signiﬁcant weight loss was expe-
rienced by both groups when administered MPH with respect
to the saline (control: −1.752± 0.410% BW, p = 0.003; lesion:
−1.968± 0.628% BW, p = 0.011; Figures 2A,B). No signiﬁcant
difference was observed in either the absolute or percentage
change in BW between the lesion and control groups within one
treatment.
FOOD INTAKE
Lesion vs. control animals displayed no signiﬁcant difference in
baseline FI (p = 0.183). A reduction in FI compared to baseline
was observed as a trend in both control (92.0± 2.4% of baseline,
p = 0.131) and lesion (87.4± 3.9% of baseline, p = 0.288) groups
when receiving injections of saline.When treated withMPH, a sig-
niﬁcant reduction in FI relative to saline injection was seen in the
control (80.1± 4.1% of saline, p = 0.002) and lesion (76.9± 3.6%
of saline, p = 0.008) groups (Figures 2C,D).
Table 1 | Characteristics of experimental groups.
Control Lesion p-Value
Pre-surgery BW (g) 295.3±5.8 300.4±5.7 0.539
Pre-surgery body length (mm) 217.4±1.4 216.1±1.4 0.533
Pre-surgery Lee index 0.306±0.001 0.310±0.002 0.122
1 day post-surgery BW (g) 302.4±4.7 325.3±7.2 0.023
3week post-surgery BW (g) 383.9±8.2 428.6±15.9 0.034
3week post-surgery FI (g) 27.3±0.6 31.5±1.1 0.002
Pre-treatment BW (g) 674.0±25.5 800.7±55.6 0.035(a)
Pre-treatment body length (mm) 273.6±3.5 265.6±6.3 0.291
Pre-treatment Lee index 0.320±0.002 0.349±0.010 0.025
Post-treatment BW (g) 661.7±23.0 783.3±50.5 0.029(a)
Δ BW during treatment (g) −12.3±3.3 −17.4±6.1 0.237
Post-treatment Lee index 0.318±0.002 0.347±0.009 0.021
Data are mean±SEM, p-values from 2-sided t-test, except (a)1-sided t-test.
FIGURE 2 |The effects of methylphenidate on either lesion or control
animals on change in body weight during treatment (A), percentage
change in body weight (B), average daily food intake (C), percentage
baseline (6 day average prior to treatment) food intake (D), in
methylphenidate injected (black bars) vs. saline injected (white bars)
rats.Two-way ANOVA modeling with a Bonferroni post hoc was used for
contrasts of two factors between study groups. ∗p<0.05, ∗∗p<0.01,
∗∗∗p<0.001.
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DISCUSSION
Our current study examined the inhibitory effect of MPH on FI
through daily evening i.p. injections (MPH, 20mg kg−1 in saline)
on our CMHL rat model of HO. MPH treatment signiﬁcantly
reduced FI in both the control and lesion group when compared
with saline treatments. Signiﬁcant weight loss was observed in
both groups during MPH treatment whereas no change occurred
during saline treatment. Given that drugs might be less effective
in reducing BW in HO (Danielsson et al., 2007), these results
are remarkable in that lesion group experienced similar weight
loss to the control group while being administered MPH. This
experiment also illustrates the dualism of hedonic and homeosta-
tic regulation of FI. The CMHL model of HO by nature results in
severe dysregulation of homeostatic regulatory pathways through
partial destruction of the hypothalamus. The ability of MPH to
attenuate homeostatic dysfunction reﬂects the ability of hedonic
regulation to override homeostatic pathways.
The observed weight loss is likely a result of more than just a
reduction in FI. It has been shown that i.p. injections of MPH lead
to a signiﬁcant increase in locomotor activity when compared to
both i.p. vehicle and intragastrical MPH administration (Gerasi-
mov et al., 2000). Additionally, as a psychomotor stimulant, MPH
has been used clinically to treat narcolepsy (Roth, 2007). While
locomotor activity and duration of sleep cycles were not quantiﬁed
in this experiment, they are likely confounding factors responsible
for the weight loss and should not be omitted from this discussion.
It should be noted that the MPH dose administered to rats
is signiﬁcantly higher than dosages ordinarily administered to
humans; this is to account for metabolic differences between rats
and humans. An i.p. dose of 2.5–10mg kg−1 MPH in a rat is
comparable to the clinical dosage administered to children and
adults for the treatment of ADHD (Yang et al., 2006) although a
20mg kg−1 dose is commonly used in rat studies (Crawford et al.,
1998; McDougall et al., 1999; Meririnne et al., 2001; Teo et al.,
2003). In a study by Teo et al. (2002) examining long-term (90 day)
oral gavage toxicity levels for MPH, the no-observed- effect-level
was determined to be 40mg kg−1 MPH. Given that this was a
short exploratory study, the higher 20mg kg−1 dose was used to
determine if any change in FI or BW could be observed.
We are aware of three clinical studies that have examined the
anorexic effect of MPH with differing results. One study showed
a 34% reduction in FI in obese males after administration of the
lowest effective dose of MPH (0.5mg kg−1 in seven of nine sub-
jects; Leddy et al., 2004); where a similar study reported an 11%
reduction in energy intake followingMPH administration in both
obese and non-obese adults (0.5mg kg−1; Goldﬁeld et al., 2007).
In contrast, a third study in obese and non-obese adults found a
reduction in FI along with lower appetite and food craving ratings
following MPH (0.5mg kg−1) administration in everyone except
obese males. The obese males experienced increases in all three
categories after MPH administration (Davis et al., 2011). The
results in our model are comparable to the Leddy et al. (2004)
and Goldﬁeld et al. (2007) studies with a 19.9 and 23.1% decrease
in FI in control and lesion animals respectively following MPH
administration when compared to saline treatment.
In our presented case report, the patient experienced signiﬁcant
weight gain and hyperphagia following resection of a CP that was
unable to be mediated by lifestyle modiﬁcation. MPH dosage was
gradually increased to a dose that resulted in sustained decrease
in BMI. These ﬁndings are signiﬁcant in that MPH treatment has
resulted in 87weeks of nearly consistent reduction of BMI in a
patient with HO independent of an exercise regimen. Moreover,
the last 56weeks after ﬁnal dosage adjustment have resulted in
even more dramatic reduction in BMI. These results indicate that
MPH may be a potential therapeutic for weight loss in HO.
The mechanism by which MPH induces anorexia is not com-
pletely known, although it is attributed to being an effect of MPH
action on the dopaminergic system to elicit a reward response. It
has been shown that MPH increases DA signaling through actions
at the synapse, speciﬁcally, through blockade of DA reuptake into
the presynaptic terminal, increasing availability of pre-synaptic
DA D2 autoreceptors and activation of D1 receptors on the post-
synaptic neuron (Wilens, 2008). It is possible that MPH elicits a
reward response normally induced by FI, therefore suppressing the
normal drive to eat. Interestingly, imaging studies have shown that
striatal DAD2 receptors are reduced in obese subjects compared to
non-obese controls and in proportion to their BMI (Wang et al.,
2001). Furthermore, in morbidly obese subjects, DA D2 recep-
tor availability was associated withmetabolic activity in prefrontal
cortical regions implicated in the regulation of FI and hyperphagia
(Volkow et al., 2009). This suggests that obese individuals have a
dysfunction in theirDAsystems and therefore donothave the same
capacity to elicit reward and thus compensate with increased FI.
Several limitations exist in this exploratory experimental
design; most notable is the relatively short duration of treatment.
Clinically, the anorexic side effect of MPH has been observed to
decrease over time, therefore a longer exposure is needed in follow
up experiments. In addition, the current study did not focus on
the hormone changes associated with this model and treatment.
Additionally, in humans the therapeutic effect of MPH requires
sustained brain levels, a condition that is not easily met in rats due
to their high rate of clearance of MPH as indicated by the relatively
short half-life. In the current study this was addressed by admin-
istering a single large dose once per day that would effectively
saturate DA transporters for a longer time. In future experiments
this will be addressed through the use of several smaller doses
administered over the course of the day or implantation of amicro
infusion pump. Other factors this experiment did not directly
address are any potential effects due to changes in psychomotor
stimulation or alterations in the animal’s sleep cycle. Finally, given
the potential variability of the lesions, the study size (n = 7 per
group) is rather small and will be expanded in future studies.
In conclusion, the results of this exploratory study indicate that
MPH signiﬁcantly attenuates FI and elicits BW loss in our novel
CMHL rat model. These results correlate well with our clinical
observations in patients with HO as well as previous clinical stud-
ies reported by others on the anorexic effect of MPH in normal
weight and obese subjects. The presented results are signiﬁcant
in that they present a model, which may be used to elucidate the
mechanisms by which MPH improves some of the most distress-
ing sequelae of HO. A better understanding of these mechanisms
could illuminate new targets for future drug therapies for the
treatment of HO. This reinforces the need for future hypothesis
driven studies focused on the underlyingmechanisms that address
changes in hormones (leptin, gut hormones), insulin resistance
and body composition.
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